IGF1R/IR Mediates Resistance to BRAF and MEK Inhibitors in BRAF-Mutant Melanoma

SIMPLE SUMMARY: Melanoma accounts for only 4% of skin cancer, but is the major cause of skin cancer related deaths. The use of dabrafenib (BRAF inhibitor) and trametinib (MEK inhibitor), two FDA approved drugs to treat patients with BRAFV600E melanoma, is limited in the clinic due to the development...

Descripción completa

Detalles Bibliográficos
Autores principales: Patel, Hima, Mishra, Rosalin, Yacoub, Nour, Alanazi, Samar, Kilroy, Mary Kate, Garrett, Joan T.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616282/
https://www.ncbi.nlm.nih.gov/pubmed/34831014
http://dx.doi.org/10.3390/cancers13225863

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8616282/
https://www.ncbi.nlm.nih.gov/pubmed/34831014
http://dx.doi.org/10.3390/cancers13225863

Ejemplares similares